NAD+ Precursors and Intestinal Inflammation : Therapeutic Insights Involving Gut Microbiota
Niño-Narvión, Julia (Institut d'Investigació Biomèdica Sant Pau)
Rojo López, Marina Idalia (Institut d'Investigació Biomèdica Sant Pau)
Martinez-Santos, Patricia (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Rossell, Joana (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Ruiz-Alcaraz, Antonio J. (Universidad de Murcia (UMU))
Alonso Pedrol, Núria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ramos-Molina, Bruno (Instituto Murciano de Investigación Biosanitaria)
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau)
Julve i Gil, Josep (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	The oxidized form of nicotinamide adenine dinucleotide (NAD+) is a critical metabolite for living cells. NAD+ may act either as a cofactor for many cellular reactions as well as a coenzyme for different NAD+-consuming enzymes involved in the physiological homeostasis of different organs and systems. In mammals, NAD+ is synthesized from either tryptophan or other vitamin B3 intermediates that act as NAD+ precursors. Recent research suggests that NAD+ precursors play a crucial role in maintaining the integrity of the gut barrier. Indeed, its deficiency has been associated with enhanced gut inflammation and leakage, and dysbiosis. Conversely, NAD+-increasing therapies may confer protection against intestinal inflammation in experimental conditions and human patients, with accumulating evidence indicating that such favorable effects could be, at least in part, mediated by concomitant changes in the composition of intestinal microbiota. However, the mechanisms by which NAD+-based treatments affect the microbiota are still poorly understood. In this context, we have focused specifically on the impact of NAD+ deficiency on intestinal inflammation and dysbiosis in animal and human models. We have further explored the relationship between NAD+ and improved host intestinal metabolism and immunity and the composition of microbiota in vivo. Overall, this comprehensive review aims to provide a new perspective on the effect of NAD+-increasing strategies on host intestinal physiology.
Grants:	Instituto de Salud Carlos III PI21/00770 Instituto de Salud Carlos III PI21/00817 Ministerio de Economía y Competitividad CB15/00071
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Aging ; Biomarker ; Colitis ; Diabetes mellitus ; Intestinal bowel disease ; Metabolomics ; Niacin ; Nicotinamide ; Pellagra ; Therapy
Published in:	Nutrients, Vol. 15 Núm. 13 (july 2023) , p. 2992, ISSN 2072-6643

DOI: 10.3390/nu15132992
PMID: 37447318

24 p, 1.2 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles